IP Library Granted Patent US 10,821,176
Granted Patent B2
US 10,821,176 · App. 16/504,716 · Granted Nov 3, 2020

Lipidated immune response modifier compound compositions, formulations, and methods

Inventor: Paul D. Wightman (St. Paul, MN)
Assignee: 3M Innovative Properties Company
A61K39/39A61K9/0019A61K9/10A61K9/127A61K31/437A61K31/47A61K39/0011A61K39/145A61K47/26C07D471/04C12N7/00A61K2039/54A61K2039/55511A61K2039/55555A61K2039/55572A61K2039/572C12N2760/16134Y02A50/41Y02A50/412
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,821,176
App. No.
16/504,716
Granted
Nov 3, 2020
Kind
B2
Abstract

The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.

Claims (4)

1. A method of treating a neoplastic disease, the method comprising administering the compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide, or a pharmaceutically acceptable salt thereof, to a human or animal having the neoplastic disease.

2. The method of claim 1 , wherein the compound is in a liposome formulation.

3. The method of claim 1 , wherein the compound is administered directly into a localized tumor mass.

4. The method of claim 1 , further including administration of a cancer vaccine antigen.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: 3M INNOVATIVE PROPERTIES COMPANY
To: SOLVENTUM INTELLECTUAL PROPERTIES COMPANY
Reel/Frame 066435/0347 →